How delayed and non-adherent treatment contribute to onward transmission of malaria: a modelling study
Introduction Artemether-lumefantrine (AL) is the most widely-recommended treatment for uncomplicated Plasmodium falciparum malaria. Its efficacy has been extensively assessed in clinical trials. In routine healthcare settings, however, its effectiveness can be diminished by delayed access to treatme...
Saved in:
| Main Authors: | John Bradley, Teun Bousema, Joseph D Challenger, Bronner P Gonçalves, Katia Bruxvoort, Alfred B Tiono, Azra C Ghani, Lucy C Okell |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-12-01
|
| Series: | BMJ Global Health |
| Online Access: | https://gh.bmj.com/content/4/6/e001856.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies.
by: Jamie T Griffin, et al.
Published: (2010-08-01) -
The potential contribution of mass treatment to the control of Plasmodium falciparum malaria.
by: Lucy C Okell, et al.
Published: (2011-01-01) -
Asymptomatic Clostridium difficile colonisation and onward transmission.
by: David W Eyre, et al.
Published: (2013-01-01) -
How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs.
by: Katia Bruxvoort, et al.
Published: (2014-01-01) -
From 2019 Onwards …
by: Dinesh Kadam
Published: (2019-01-01)